Understanding Patient Derived Xenograft Model
Cancer is a complex disease with high heterogeneity even within the same type and stage of cancer. No two tumors are exactly alike as they differ markedly in their genetic makeup and molecular characteristics. The differences arise due to genetic mutations acquired during tumor evolution and progression. Traditional cell line models fail to fully capture this intrinsic tumor heterogeneity seen in patients. Patient derived xenograft (PDX) models, on the other hand, can preserve the heterogeneous tumor ecosystems in their native form.
Patient Derived Xenograft Model are established by directly transplanting fresh tumor tissues obtained from cancer patients into immune-deficient mice. Unlike cell lines, PDXs retain the original complex composition of malignant and non-malignant cells along with the tumor microenvironment. They mimick human tumors more closely in terms of histoarchitecture, genomic alterations, signaling pathways and response to therapies. Importantly, PDXs preserve the intratumoral genetic diversity within an individual patient's cancer.
Reflecting Clinical Patient Derived Xenograft Model
Studies have shown that PDX models retain key features of the donor patient tumors, sometimes over multiple passages in mice. Global gene expression, mutational landscape and protein expression patterns of the engrafted tumors have been found to faithfully recapitulate those of the original clinical specimens. PDXs can also reproduce the heterogeneity observed between spatially distinct regions of the same primary tumor, reflecting the clonal evolution in the patient. Some models have demonstrated stable retention of tumor phenotypes, genetics and biomarkers even after years of propagation in mice.
PDXs serve as avatars of patient tumors that allow researchers to investigate drug responses and resistance mechanisms in a setting that closely parallels clinical tumor biology. Responses of PDX models to anti-cancer agents have been shown to correlate well with patient outcomes in initial clinical trials, validating them as clinically relevant preclinical platforms for precision oncology drug development.
Evaluating Novel Combination Therapies
With advancements in targeted therapies and immunotherapies, combining different agents is emerging as a promising strategy to tackle treatment resistance and achieve deeper and more durable responses in cancer. However, rationally designing effective combination regimens requires an in-depth understanding of underlying molecular mechanisms.
PDX models are ideal for evaluating novel multi-drug combinations and sequential treatment strategies. Their preservation of intratumoral heterogeneity facilitates investigation of clonal selection processes under therapeutic pressures. Researchers can study how combination regimens impact signaling pathways and immune responses within the native tumor microenvironment. Such mechanistic insights from PDX studies are guiding the design of optimized treatment sequences and biomarker-driven clinical trials of combinatorial approaches.
Personalized Medicine Applications
An increasing number of biopharma companies are establishing living biobanks of PDX models derived from a wide range of cancer types and stages. Genomic and drug response data on these large PDX collections provide a knowledgebase to power applications in personalized medicine.
In Summary, oncologists can utilize PDX avatars of their patients' tumors to predict therapeutic vulnerabilities and optimize treatment plans. For patients failing standard therapies or with rare cancers, PDXs help identify eligible targeted and immuno-oncology clinical trials. In the future, commercialized PDX-based diagnostic tests may inform clinical decision making with high accuracy. Overall, the use of PDX models is accelerating the realization of truly personalized precision oncology approaches.
Get More Insights on- Patient Derived Xenograft Model
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)